MedTrace Logo

Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty

NCT05750758 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2024-02-23

No results posted yet for this study

Summary

The target population of this interventional study was ACS patients with drug-coated balloons. The main discussion : 1.1 months of rivaroxaban combined with dual antiplatelet therapy compared with dual antiplatelet therapy alone, late lumen loss at 6 months. 2. To determine the safety of the regimen with bleeding events as the end point. Subjects were randomly assigned to two groups, one receiving routine DAPT for six months and one receiving DAPT plus one month of rivaroxaban 2.5 mg bid

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

rivaroxaban

rivaroxaban 2.5mg bid for 1m

Sponsors & Collaborators

  • Henan Institute of Cardiovascular Epidemiology

    lead OTHER

Principal Investigators

  • Muwei Li, MD · Fuwai central China cardiovascular hospotial

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-20
Primary Completion
2023-08-10
Completion
2023-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05750758 on ClinicalTrials.gov